VSL#3 Improves Symptoms in Children With Irritable Bowel Syndrome: A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Crossover Study

  title={VSL\#3 Improves Symptoms in Children With Irritable Bowel Syndrome: A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Crossover Study},
  author={Stefano Guandalini and Giuseppe Magazz{\`u} and Andrea Chiaro and Valeria La Balestra and Giovanni Di Nardo and Sarath Gopalan and Alexander P. Sibal and Claudio Romano and Roberto Berni Canani and Paolo Lionetti and Mala Setty},
  journal={Journal of Pediatric Gastroenterology and Nutrition},
Background and Objectives: Irritable bowel syndrome (IBS) is a common problem in pediatrics, for which no safe and effective treatment is available. Probiotics have shown some promising results in adult studies, but no positive study has been published on pediatric age. We aimed at investigating the efficacy of VSL#3 in a population of children and teenagers affected by IBS, in a randomized, double-blind, placebo-controlled, crossover study conducted in 7 pediatric gastroenterology divisions… 

A Mixture of 3 Bifidobacteria Decreases Abdominal Pain and Improves the Quality of Life in Children With Irritable Bowel Syndrome: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Trial

In children with IBS a mixture of Bifidobacterium infantis M-63, breve M-16V, and longum BB536 is associated with improvement in AP and QoL and these findings were not confirmed in FD subjects.

Probiotic for irritable bowel syndrome in pediatric patients: a randomized controlled clinical trial

Lactobacillus GG at a concentration of 1×1010 cfu/ml for a period of four weeks can lessen the severity of the patients’ pain and improve the functional scale in patients with irritable bowel syndrome.

Efficacy of Bacillus coagulans Unique IS2 in treatment of irritable bowel syndrome in children: a double blind, randomised placebo controlled study.

This study demonstrates the efficacy of B. coagulans Unique IS2 in reducing the symptoms of Irritable Bowel Syndrome in children in the age group of 4-12 years.

Lactobacillus reuteri DSM 17938 in the Treatment of Functional Abdominal Pain in Children: RCT Study

Administration of L reuteri DSM 17938 was associated with a possible reduction of the intensity of pain and significantly more days without pain in children with FAP and IBS.

Efficacy of probiotic adjuvant therapy for irritable bowel syndrome in children: A systematic review and meta-analysis

Objective Irritable bowel syndrome (IBS) affects children’s quality of life and learning. The purpose of this research was to systematically evaluate the efficacy of probiotic adjuvant therapy for

Effects of probiotic supplementation on abdominal pain severity in pediatric patients with irritable bowel syndrome: a systematic review and meta-analysis of randomized clinical trials

It is demonstrated that probiotic supplementation has a significant effect on reducing abdominal pain in pediatric patients with IBS.

Probiotics for Irritable Bowel Syndrome: Clinical Data in Children.

Probiotics are emerging as new therapeutic tools in FGIDs, due to the recognition of the importance of gut microbiota in influencing brain-gut interactions, and of the role played by intestinal infections in the genesis of AP-FGIDs.

Studies on inflammatory bowel disease and functional gastrointestinal disorders in children and adults

Ongoing (irritable bowel syndrome-type) gastrointestinal symptoms in quiescent IBD are much less common in children compared to adults, and these symptoms appear to be unrelated to inflammation, both in children and in adults.



Bacterial supplementation in the irritable bowel syndrome. A randomised double-blind placebo-controlled crossover study.

  • M. O'SullivanC. O'Morain
  • Medicine
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • 2000

Meta-analysis of probiotics for the treatment of irritable bowel syndrome.

It is suggested that probiotic use may be associated with improvement in IBS symptoms compared to placebo, and these results should be interpreted with caution, given the methodological limitations of contributing studies.

Postinfectious Irritable Bowel Syndrome—A Meta-Analysis

The results suggest that the long-term benefit of reduced PI-IBS may be gained from primary prevention of IGE, and a pooled risk estimate revealing a sevenfold increase in the odds of developing IBS following IGE.

Risk of irritable bowel syndrome after an episode of bacterial gastroenteritis in general practice: influence of comorbidities.

Efficacy of an Encapsulated Probiotic Bifidobacterium infantis 35624 in Women with Irritable Bowel Syndrome

B. infantis 35624 at a dose of 1 × 108 cfu was significantly superior to placebo and all other bifidobacterium doses for the primary efficacy variable of abdominal pain as well as the composite score and scores for bloating, bowel dysfunction, incomplete evacuation, straining, and the passage of gas at the end of the 4-wk study.

Almost all irritable bowel syndromes are post-infectious and respond to probiotics: controversial issues.

The discovery that an infective episode may trigger the development of PI-IBS has not substantially changed the clinical management of this subset of patients compared to the classical (non-infective) form of IBS and a number of issues still remain to be elucidated.